Targeting the cancer stem cell marker, aldehyde dehydrogenase 1, to circumvent cisplatin resistance in NSCLC

Non-small cell lung cancer (NSCLC) accounts for a large proportion of cancer deaths and is characterized by low treatment response rates and poor overall prognosis. In the absence of specific treatable mutations, cisplatin-based chemotherapy plays an important role in the treatment of this disease....

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
izdano v:Oncotarget
Main Authors: MacDonagh, Lauren, Gallagher, Michael F., Ffrench, Brendan, Gasch, Claudia, Breen, Eamon, Gray, Steven G., Nicholson, Siobhan, Leonard, Niamh, Ryan, Ronan, Young, Vincent, O'Leary, John J., Cuffe, Sinead, Finn, Stephen P., O'Byrne, Kenneth J., Barr, Martin P.
Format: Artigo
Jezik:Inglês
Izdano: Impact Journals LLC 2017
Teme:
Research Paper
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC5641151/
https://ncbi.nlm.nih.gov/pubmed/29069808
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.19881
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki